• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Caribou Biosciences Inc.

    3/5/26 5:11:55 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRBU alert in real time by email
    S-8 1 d118168ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 5, 2026

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Caribou Biosciences, Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware   45-3728228

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    2929 7th Street, Suite 105

    Berkeley, CA

      94710
    (Address of Principal Executive Offices)   (Zip Code)

    Caribou Biosciences, Inc. 2021 Equity Incentive Plan

    Caribou Biosciences, Inc. 2021 Employee Stock Purchase Plan

    (Full Title of the Plan)

    Rachel E. Haurwitz, Ph.D.

    President and Chief Executive Officer

    Caribou Biosciences, Inc.

    2929 7th Street, Suite 105

    Berkeley, California 94710

    (510) 982-6030

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    Ashok W. Mukhey, Esq.

    Reed Smith LLP

    1901 Avenue of the Stars, Suite 700

    Los Angeles, California 90067

    Telephone: (310) 734-5200

     

    Barbara G. McClung, Esq.

    Caribou Biosciences, Inc.

    2929 7th Street, Suite 105

    Berkeley, California 94710

    Telephone: (510) 982-6030

     

    Jeffrey G. Aromatorio, Esq.

    Reed Smith LLP

    225 Fifth Avenue

    Pittsburgh, Pennsylvania 15222

    Telephone: (412) 288-3364

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is filed by Caribou Biosciences, Inc., a Delaware corporation (the “Registrant”), relating to 4,757,184 shares of its common stock, par value $0.0001 per share (the “Common Stock”), to be issued pursuant to the Registrant’s 2021 Equity Incentive Plan (“2021 EIP”) and 951,436 shares of Common Stock to be issued pursuant to the Registrant’s 2021 Employee Stock Purchase Plan (“2021 ESPP”), which Common Stock is in addition to the 22,932,054 shares of Common Stock already issuable under the 2021 EIP and the 3,532,196 shares of Common Stock already issuable under the 2021 ESPP as registered on the Registrant’s Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on July 26, 2021 (File No. 333-258173), Form S-8 filed with the Commission on March 21, 2022 (File No.  333-263750), Form S-8 filed with the Commission on March 9, 2023 (File No. 333-270431), Form S-8 filed with the Commission on March  11, 2024 (File No. 333-277827), and Form S-8 filed with the Commission on March 10, 2025 (File No. 333-285685) (collectively, the “Prior Registration Statements”). These additional shares of Common Stock have been reserved for issuance as a result of the operation of the “evergreen” provisions in the Registrant’s 2021 EIP and 2021 ESPP, which provide that the total number of shares subject to such plans may be increased each year pursuant to a specified formula.

    This Registration Statement relates to securities of the same class as that to which the Prior Registration Statements relate, and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”).

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    In this registration statement, Caribou Biosciences, Inc. is sometimes referred to as “Registrant,” “we,” “us,” or “our.”

    Item 3. Incorporation of Documents by Reference.

    The following documents previously filed by Caribou Biosciences, Inc. (the “Registrant”) with the Commission are incorporated by reference into this Registration Statement:

     

    (a)

    Registrant’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Commission on March 5, 2026; and

     

    (b)

    The description of the Registrant’s Common Stock which is contained in a registration statement on Form 8-A filed on July 19, 2021 (File No. 001-40631) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as updated by the description of the Registrant’s capital stock contained in Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K, for the fiscal year ended December 31, 2021, including any amendment or report filed for the purpose of updating such description.

    All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this registration statement which indicates that all of the shares of common stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference into this registration statement and to be a part hereof from the date of the filing of such documents; except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under current


    Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, that is not deemed filed under such provisions. For the purposes of this registration statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

    Under no circumstances will any information filed under current Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

    Item 8. Exhibits.

    Reference is made under this Item 8 to the exhibit index included in this Registration Statement.


    Exhibit Index

     

    Exhibit

    Number

      

    Exhibit Description

    4.1    Amended and Restated Certificate of Incorporation, as currently in effect (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40631), filed with the Commission on July 28, 2021).
    4.2    Amended and Restated Bylaws, as currently in effect (incorporated herein by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-40631), filed with the Commission on July 28, 2021).
    5.1    Opinion of Reed Smith LLP.
    23.1    Consent of Independent Registered Public Accounting Firm.
    23.2    Consent of Reed Smith LLP (reference is made to Exhibit 5.1).
    24.1    Power of Attorney (reference is made to the signature page hereto).
    99.1    2021 Equity Incentive Plan (incorporated herein by reference to Exhibit 99.6 to the Registrant’s Registration Statement on Form S-8 (File No. 333-258173), filed with the Commission on July 26, 2021).
    99.2    Form of Employee Stock Option Agreement under the 2021 Equity Incentive Plan of the Registrant (incorporated herein by reference to Exhibit 10.50 to the Registrant’s Annual Current Report on Form 10-K (File No. 001-40631) for the period ended December 31, 2021, filed with the Commission on March 21, 2022).
    99.3    Form of Non-Employee Director Stock Option Agreement under the 2021 Equity Incentive Plan of the Registrant (incorporated herein by reference to Exhibit 10.51 to the Registrant’s Annual Report on Form 10-K (File No. 001-40631) for the period ended December 31, 2021, filed with the Commission on March 21, 2022).
    99.4    Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Equity Incentive Plan of the Registrant (incorporated herein by reference to Exhibit 10.52 to the Registrant’s Annual Report on Form 10-K (File No. 001-40631) for the period ended December 31, 2021, filed with the Commission on March 21, 2022).
    99.5    Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Equity Incentive Plan of the Registrant (incorporated by reference to Exhibit 10.1 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40631) for the period ended September 30, 2022, filed with the Commission on November 8, 2022).
    99.6    Form of Performance Stock Unit Award Grant Notice and Performance Stock Unit Award Agreement under the 2021 Equity Incentive Plan of the Registrant (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40631) for the period ended September 30, 2022, filed with the Commission on November 8, 2022).
    99.7    Form of Performance-Based Stock Option Agreement under the 2021 Equity Incentive Plan of the Registrant (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40631) for the period ended September 30, 2025, filed with the Commission on November 12, 2025).
    99.8    2021 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 99.7 to the Registrant’s Registration Statement on Form S-8 (File No. 333-258173), filed with the Commission on July 26, 2021).
    107    Filing Fee Table


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Berkeley, State of California, on this 5th day of March, 2026.

     

    Caribou Biosciences, Inc.
    By:  

    /s/ Rachel E. Haurwitz

      Rachel E. Haurwitz
      President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Rachel E. Haurwitz, Barbara G. McClung, and Sriram Ryali and each of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature

      

    Title

      

    Date

    /s/ Rachel E. Haurwitz

    Rachel E. Haurwitz

      

    President and Chief Executive Officer and Director

    (Principal Executive Officer)

       March 5, 2026

    /s/ Sriram Ryali

    Sriram Ryali

      

    Chief Financial Officer

    (Principal Financial Officer and Principal Accounting Officer)

       March 5, 2026

    /s/ Scott Braunstein

    Scott Braunstein

       Director    March 5, 2026

    /s/ Andrew Guggenhime

    Andrew Guggenhime

       Director    March 5, 2026

    /s/ David Johnson

    David Johnson

       Director    March 5, 2026

    /s/ Dara Richardson-Heron

    Dara Richardson-Heron

       Director    March 5, 2026

    /s/ Natalie Sacks

    Natalie Sacks

       Director    March 5, 2026

    /s/ Nancy Whiting

    Nancy Whiting

       Director    March 5, 2026

    /s/ Ran Zheng

    Ran Zheng

       Director    March 5, 2026
    Get the next $CRBU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRBU

    DatePrice TargetRatingAnalyst
    6/3/2024$13.00 → $3.00Outperform → In-line
    Evercore ISI
    11/8/2023Neutral
    Cantor Fitzgerald
    10/31/2023$13.00Outperform
    Evercore ISI
    7/11/2023$23.00Buy
    Truist
    2/18/2022$22.00Outperform
    RBC Capital
    2/14/2022$19.00Buy
    Brookline Capital
    12/1/2021$36.00Outperform
    Oppenheimer
    11/30/2021$28.00Buy
    H.C. Wainwright
    More analyst ratings

    $CRBU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Kelly Timothy P sold $12,020 worth of shares (6,228 units at $1.93), decreasing direct ownership by 8% to 73,125 units (SEC Form 4)

    4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

    2/27/26 4:01:13 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Technology Officer Kelly Timothy P was granted 45,000 shares and sold $6,168 worth of shares (3,147 units at $1.96), increasing direct ownership by 112% to 79,353 units (SEC Form 4)

    4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

    2/24/26 8:54:41 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Legal Officer Mcclung Barbara G was granted 45,000 shares and sold $13,598 worth of shares (6,938 units at $1.96), increasing direct ownership by 9% to 481,564 units (SEC Form 4)

    4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

    2/24/26 8:54:36 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRBU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Haurwitz Rachel E. bought $20,400 worth of shares (20,000 units at $1.02) (SEC Form 4)

    4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

    3/17/25 8:01:22 AM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Ryali Sriram bought $24,651 worth of shares (17,360 units at $1.42) (SEC Form 4)

    4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

    1/30/25 4:02:12 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRBU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for fourth quarter and full year 2025 and provided an overview of recent corporate highlights. "2025 was a year of strong execution for Caribou as we advance two potentially best-in-class allogeneic CAR-T cell therapy programs," said Rachel Haurwitz, PhD, Caribou's president and CEO. "The vispa-cel ANTLER phase 1 data in second-line LBCL patients demonstrated efficacy and durability on par with autologous CAR-T therapy and solidified our confidence that this program is delivering on the prom

    3/5/26 4:05:00 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Caribou Biosciences to Participate in Upcoming Investor Conferences

    BERKELEY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences: Citi 2026 Virtual Oncology Leadership Summit, VirtualFebruary 19, 2026, with a fireside chat at 10:45 AM ET Leerink Global Healthcare Conference, Miami, FLMarch 10, 2026, with a fireside chat at 8:00 AM ETWebcast For more information and link to the Leerink webcast, please visit the Events page on Caribou's website. The webcast will be available on the Caribou website for at least 30 days after the event. About Caribou Biosciences, Inc.Cari

    2/12/26 4:05:00 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®

    Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programs Vispa-cel (CB-010) ANTLER phase 1 translational and clinical data demonstrate efficacy and durability that is on par with autologous CAR-T cell therapy in 2L LBCL patients CB-011 CaMMouflage phase 1 translational and clinical data correlate CAR-T cell expansion with deep, durable responses and support the regimen selected for dose expansion BERKELEY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced presentations at the 2026 Tandem

    2/4/26 8:00:00 AM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRBU
    SEC Filings

    View All

    SEC Form S-8 filed by Caribou Biosciences Inc.

    S-8 - Caribou Biosciences, Inc. (0001619856) (Filer)

    3/5/26 5:11:55 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Caribou Biosciences Inc.

    10-K - Caribou Biosciences, Inc. (0001619856) (Filer)

    3/5/26 4:09:09 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Caribou Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Caribou Biosciences, Inc. (0001619856) (Filer)

    3/5/26 4:07:40 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRBU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Caribou Biosciences downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Caribou Biosciences from Outperform to In-line and set a new price target of $3.00 from $13.00 previously

    6/3/24 7:23:52 AM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on Caribou Biosciences

    Cantor Fitzgerald initiated coverage of Caribou Biosciences with a rating of Neutral

    11/8/23 7:19:33 AM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evercore ISI initiated coverage on Caribou Biosciences with a new price target

    Evercore ISI initiated coverage of Caribou Biosciences with a rating of Outperform and set a new price target of $13.00

    10/31/23 8:58:42 AM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRBU
    Leadership Updates

    Live Leadership Updates

    View All

    Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer

    BERKELEY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sri Ryali as chief financial officer, effective immediately. Mr. Ryali brings 20 years of finance and commercial experience in the biopharmaceutical industry to his role, and he will be responsible for the strategic leadership of the corporate finance, investor relations, and corporate communications functions. He will report to Rachel Haurwitz, PhD, Caribou's president and chief executive officer. "I am excited to welcome Sri to Caribou at the beginning of this pivotal year for our organiz

    1/2/25 8:00:00 AM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer

    -- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies -- BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Tina Albertson, MD, PhD, as chief medical officer. Dr. Albertson brings 15 years of experience leading clinical drug development of cellular therapies and biologics. She will be responsible for strategic leadership of the clinical, regulatory, and medical affairs functions, and provide medical and operational leadership of Caribou's four clin

    8/12/24 8:00:00 AM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board

    -- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Terri Laufer, MD, to its scientific advisory board. Dr. Laufer is a leading rheumatologist known for her extensive research into immune cell regulation and dysfunction that leads to autoimmune diseases. She is an emeritus associate professor of medicine at the Perelman School of Medicine at the University of Pennsylvania and an attending rheumatologist at the Penn Presbyterian Med

    7/9/24 8:00:00 AM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRBU
    Financials

    Live finance-specific insights

    View All

    Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

    First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma450 million cell dose is the recommended dose for expansion (RDE); dose expansion to initiate by year end and data expected in 202692% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-naïve cohort treated at the RDE with the selected lymphodepletion regimenConference call and webcast scheduled for today at 8:00 am ET BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced its first clinical data

    11/3/25 7:00:00 AM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

    Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with longer-term follow-up on patients who received optimized vispa-cel (N=35) 82% ORR, 64% CR rate, 51% PFS at 12 months in patients prospectively enrolled in partial HLA matching confirmatory cohort (N=22)86% ORR, 63% CR rate, 53% PFS at 12 months in patients who received vispa-cel with an optimized profile (N=35) Vispa-cel is generally well-tolerated, allowing for administration in the outpatient settingData highlight vispa-cel's potential as best-in-class allogeneic CAR-T cell therapy for LBCLConference c

    11/3/25 7:00:00 AM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

    -- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) -- -- Plan to enroll ~20 additional 2L LBCL patients in ANTLER to confirm that partial HLA matching improves patient outcomes; initial data expected in H1 2025 -- -- Caribou expects to initiate a pivotal trial for CB-010 in H2 2025, upon confirmation of improved outcomes in partially HLA matched cohort -- -- Off-the-shelf CB-010 is partially HLA matched to patient within current screening timelines -- -- KOL webcast discussion of data from 46

    6/2/24 7:00:00 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRBU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Caribou Biosciences Inc.

    SC 13D/A - Caribou Biosciences, Inc. (0001619856) (Subject)

    12/6/24 4:06:56 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Caribou Biosciences Inc.

    SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

    11/14/24 7:53:54 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Caribou Biosciences Inc.

    SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

    11/14/24 6:08:51 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care